×
About 2,695 results

ALLMedicine™ Merkel Cell Carcinoma Center

Research & Reviews  930 results

Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma...
https://doi.org/10.1016/j.jaad.2022.05.019
Journal of the American Academy of Dermatology; Tieniber AD, Shannon A et. al.

May 20th, 2022 - Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis.|2022|Tieniber AD,Shannon A,Carr MJ,Sun J,Landa K,|

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04291885

May 20th, 2022 - The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The pr...

Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
https://clinicaltrials.gov/ct2/show/NCT04975152

May 19th, 2022 - The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating Merkel Cell Carcinoma.

Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therap...
https://doi.org/10.1016/j.jneuroim.2022.577882
Journal of Neuroimmunology; Dinoto A, McKeon A et. al.

May 18th, 2022 - A 67-years-old woman developed subacute oculomotor nerve palsy and cerebellar gait instability while receiving avelumab as immunotherapy for Merkel cell carcinoma. Brain MRI revealed oculomotor nerve T2/FLAIR hyperintensity and contrast enhancemen...

Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas ...
https://doi.org/10.1007/s12022-022-09716-2 10.1146/annurev-pathmechdis-012419-032817 10.1016/j.det.2019.06.002 10.1245/s10434-021-09987-9 10.1001/jamadermatol.2020.4102 10.1016/j.jaad.2017.10.028 10.1001/jamadermatol.2014.124 10.1016/j.jid.2021.04.007 10.1111/1346-8138.15875 10.1158/1078-0432.CCR-18-4159 10.1016/j.tvr.2021.200232 10.1111/cup.13910 10.1016/j.jid.2016.10.028 10.1158/1078-0432.CCR-20-0864 10.1111/apm.12122 10.3390/cancers6031328 10.1309/AJCPIKDZM39CRPNC 10.1245/s10434-012-2509-x 10.1016/j.jaad.2020.02.034 10.1111/cup.12160 10.1186/s12885-017-3233-5 10.1097/00000372-200412000-00003 10.1111/j.1600-0560.2006.00613.x 10.1007/s12022-021-09669-y 10.1371/journal.pone.0252099 10.1016/j.humpath.2012.11.021 10.1007/s00403-020-02141-7 10.1016/S0190-9622(97)80122-3 10.1038/s41379-019-0394-6 10.1097/DAD.0000000000001548 10.1097/PAS.0000000000001136 10.1002/cncr.23874 10.1038/s41571-018-0103-2 10.1016/j.jaad.2012.09.036 10.1158/1078-0432.CCR-11-3020 10.1158/1078-0432.CCR-16-0392 10.1634/theoncologist.2020-0070 10.1007/s12022-019-09601-5 10.1016/j.hoc.2018.08.002 10.1016/j.jid.2020.02.031 10.1158/2326-6066.CIR-16-0210 10.1002/ijc.24676 10.1038/jid.2011.115 10.1016/j.ijom.2010.06.024 10.1111/j.1600-0560.2012.01964.x 10.1093/jnci/djp139 10.1038/s41379-019-0288-7 10.1016/j.jaad.2020.05.125 10.1016/j.humpath.2012.04.002 10.3390/cancers12040888 10.1371/journal.pone.0232517 10.1007/s12022-020-09640-3 10.1016/j.humpath.2014.12.001 10.1158/1078-0432.CCR-11-2308 10.1016/j.humpath.2010.09.011 10.1016/j.ajpath.2021.06.009 10.1186/s13058-015-0610-3 10.1158/0008-5472.CAN-08-4419 10.3892/ol.2015.3859 10.1038/modpathol.2013.250 10.1016/j.jaad.2012.07.035 10.1158/1078-0432.CCR-17-1678 10.1093/AJCP/AQAA051 10.1016/j.jdcr.2020.11.017
Endocrine Pathology; Santoro F, Maletta F et. al.

May 14th, 2022 - Merkel cell carcinoma is a rare and aggressive primary neuroendocrine carcinoma of the skin, whose pathogenesis can be traced back to UV radiation damage or Merkel cell polyomavirus (MCPyV) infection. Despite some improvements on the characterizat...

see more →

Guidelines  3 results

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0055
Journal of the National Comprehensive Cancer Network : JN... Bichakjian CK, Olencki T et. al.

Jun 13th, 2018 - This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radi...

Merkel cell carcinoma, version 1.2014.
https://doi.org/10.6004/jnccn.2014.0041
Journal of the National Comprehensive Cancer Network : JN... Bichakjian CK, Olencki T et. al.

Mar 13th, 2014 - Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative nonmelanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The NCCN Guidelines for Merkel Cell Carc...

Guidelines for the diagnosis and treatment of Merkel cell carcinoma - Cutaneous Oncolog...
https://doi.org/10.1684/ejd.2012.1694
European Journal of Dermatology : EJD; Boccara O, Girard C et. al.

Apr 14th, 2012 - Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. The epidemiological factors strongly associated with this tumor are: age over 65 years, fair skin, chronic sun exposure and immune suppression. Data are sparse in the literatu...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  23 results

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04291885

May 20th, 2022 - The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The pr...

Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
https://clinicaltrials.gov/ct2/show/NCT04975152

May 19th, 2022 - The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating Merkel Cell Carcinoma.

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
https://clinicaltrials.gov/ct2/show/NCT03599713

May 9th, 2022 - The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03787602

Apr 29th, 2022 - This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with av...

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03684785

Apr 7th, 2022 - This study will be conducted in 2 phases. Phase 1 evaluates cavrotolimod given in combination with pembrolizumab in patients with advanced solid tumors in a classical 3+3 dose escalation design, with up to five ascending dose cohorts of cavrotolim...

see more →

News  114 results

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
https://www.onclive.com/view/administration-of-rp1-through-intratumoral-injection-offers-unique-advantages-in-melanoma-treatment

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

Study Tests Novel Doublet Designed to Promote Immunity in cSCC
https://www.onclive.com/view/study-tests-novel-doublet-designed-to-promote-immunity-in-cscc

Jan 3rd, 2022 - Dan P. Zandberg, MD Investigators are testing the hypothesis that administering cetuximab (Erbitux) with an anti—PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma (cSCC). Th...

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas
https://www.onclive.com/view/pembrolizumab-chemo-not-effective-in-extrapulmonary-poorly-differentiated-neuroendocrine-carcinomas

Nov 15th, 2021 - The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs)...

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma
https://www.onclive.com/view/dr-d-angelo-on-the-incidence-and-prognosis-of-merkel-cell-carcinoma

Oct 6th, 2021 - Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the incidence and prognosis of patients with Merkel cell carcinoma (MCC). MCC is a rare cancer that affects approximately 1,000 to 2,000 individuals...

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma
https://www.onclive.com/view/novel-targets-set-to-add-to-checkpoint-blockade-success-in-merkel-cell-carcinoma

Jun 15th, 2021 - Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer for which treatment options are limited. Moreover, mortality and morbidity remain high, said James A. DeCaprio, MD, who added that the high response rates observed with checkpoint inhib...

see more →

Patient Education  5 results see all →